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Correspondence
Amphotericin B–Related
Nephrotoxicity Has an
Economic Impact on
Hospitals and Health
Systems
Sir—The recent report by Harbarth et al.
[1] is an interesting attempt to assess the
clinical and economic outcomes associ-
ated with renal toxicity after treatment
with amphotericin B. The study uses sur-
vival analysis to model the effects of ne-
phrotoxicity on length of hospital stay,
costs of hospitalization, and mortality rate.
Harbarth et al. [1] note that their single-
center results are markedly different from
the findings of previous reports [2]. Spe-
cifically, findings of Harbarth et al. [1] are
different those of our retrospective, mul-
ticenter study, which demonstrated sig-
nificant increases in the length of hospital
stay and costs for patients who experi-
enced nephrotoxicity after receiving treat-
ment with conventional and liposomal
amphotericin B.
There may be several reasons for these
differences in addition to the methodo-
logical ones identified by Harbarth et al.
[1]. One main difference lies in underlying
patient demographic characteristics. All of
the patients from our study were febrile
and neutropenic [3]. More than 50% of
the patients in our study were bone mar-
row transplant recipients. This contrasts
with the more heterogeneous population
analyzed at LDS Hospital (Salt Lake City).
A second important difference is that
175% of patients enrolled in the study by
Walsh et al. [3] received 2 concomitant
nephrotoxic agents. This critical risk factor
and potential confounding variable was
not incorporated in the study by Harbarth
et al. [1]. Lack of concomitant therapy
with nephrotoxic agents may, in part, ex-
plain the 12% incidence of nephrotoxicity
found by Harbarth and colleagues.
Also, our analysis was performed to
evaluate the pharmacoeconomics of con-
ventional and liposomal amphotericin B
within the context of a randomized, dou-
ble-blind, multicenter clinical trial. The
objective of our study was not to evaluate
the impact of nephrotoxicity solely. In-
stead, because the clinical study was not
powered to measure economic differences
from an intent-to-treat perspective, costs
associated with pivotal clinical outcomes
(namely nephrotoxicity) were examined
to allow for economic comparisons be-
tween treatment groups.
A separate analysis of a different cohort
of patients treated with lipid formulations
of amphotericin B was conducted recently
to determine factors that affect hospital
costs [4, 5]. Stepwise regression analysis
showed that length of hospital stay, ne-
phrotoxicity, number of concomitant
medications, receipt of dialysis, allogeneic
bone marrow transplantation, and dura-
tion of treatment (in days) with study drug
all affected hospital costs after the initia-
tion of lipid-based therapy.
Overall, we believe that the analysis by
Harbarth et al. [1] is valuable in promot-
ing the use of additional techniques to ex-
amine the impact of treatment-related ad-
verse events on hospital costs. However,
its findings with respect to the net impact
of amphotericin B–induced nephrotoxic-
ity should be applied with caution across
various patient populations, clinical set-
tings, institutions, and treatment deci-
sions.
Mary M. Prendergrast1 and Kuo B. Tong2
1Fujisawa Healthcare, Deerfield, Illinois;
and 2Quorum Consulting, San Francisco, California
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Reply
Sir—We appreciate the thoughtful com-
ments of Prendergast and Tong [1] re-
garding our article [2]. We have 2 com-
ments in response.
First, we did examine the independent
effect of other nephrotoxic agents on the
incidence of renal failure, as reported in a
previously published article [3]. In these
detailed analyses, treatment with cyclo-
sporine and the mean daily amphotericin
B dose were found to be independently
associated with the development of ne-
phrotoxicity. Use of amikacin tended
to increase the risk of nephrotoxicity,
whereas use of tacrolimus, furosemide, or
vancomycin was not an independent pre-
dictor of nephrotoxicity in that cohort
study [3].
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Second, we would like to underscore
one of the main messages of our article
[2], which is that the statistical methods
used for estimating the cost impact of an
adverse event have a major effect on the
results. Costs attributed to adverse events,
such as nephrotoxicity, should include
only those costs incurred after occurrence
of the adverse event. Observing an asso-
ciation between high hospital costs and
nephrotoxicity is not a reliable indicator
that nephrotoxicity is the direct cause
of the higher costs, because many con-
founding factors probably exist that are
common causes of higher cost and ne-
phrotoxicity, including factors that are un-
measured. It is not safe to assume that this
confounding is removed simply by build-
ing a multivariable regression model, par-
ticularly when criteria used for variable
inclusion are based solely on statistical sig-
nificance. The recent study [4] cited by
Prendergast and Tong [1] found that ne-
phrotoxicity was one of the factors asso-
ciated with increased costs in a multivar-
iable regression model, when all costs
incurred after study entry, both before and
after the adverse event, were grouped to-
gether. Another finding from this study
worth noting is that the agents that were
compared in the clinical trial (amphoter-
icin B lipid complex and liposomal am-
photericin B) exhibited similar efficacy but
dramatically different incidences of ad-
verse events (e.g., the incidences of ne-
phrotoxicity were 42% and 14%–15%, re-
spectively). However, total poststudy entry
costs (excluding the cost of the study
drug) across treatment groups were sim-
ilar, a finding parallel to a study by Cag-
noni et al. [5]. Thus, unconfounded, in-
tent-to-treat analyses do not support the
contention that nephrotoxicity has a large
causal effect on hospital costs.
Stephan Harbarth1 and Matthew H. Samore2
1Infection Control Program, Geneva University
Hospitals, Geneva, Switzerland; and 2Division
of Infectious Diseases, Department of Internal
Medicine, University of Utah School of Medicine,
Salt Lake City, Utah
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Human Granulocytic
Ehrlichiosis Presenting as
Acute Abdomen in an Adult
Sir—Rickettsial illnesses manifest in
many ways, and our knowledge of disease
caused by these organisms is still evolving.
We read with interest the report by Seydev
et al. [1] of human monocytic ehrlichiosis
(HME) that caused acute appendicitis in
a pregnant woman. Rocky Mountain spot-
ted fever (RMSF) can present with symp-
toms mimicking appendicitis [2], and an-
other recent article described a child with
human granulocytic ehrlichiosis (HGE),
acute abdomen, and suspected appendi-
citis [3]. To date, there have been no re-
ports in the literature of HGE presenting
as acute abdomen in an adult. Here, we
present such a case.
A 46-year-old white man was hospital-
ized for diffuse abdominal pain and fever.
His only significant medical history was
occasional abuse of 11 substance at a time.
Five days before admission to the hospital,
he noted acute onset of fever and “flulike
symptoms.” He gradually improved and
attended a party on the night before ad-
mission, where he used cocaine and con-
sumed alcohol. Subsequently, he devel-
oped diffuse, severe abdominal pain that
was localized in the right lower quadrant
(RLQ). He denied a recent history of nau-
sea, vomiting, diarrhea, and dysuria. He
was heterosexual and denied having had
unprotected sex, used injection drugs, or
recently traveled. He wasn’t receiving
medication.
In the emergency department, his tem-
perature was 38.8C, his pulse rate was 102
beats/min, his blood pressure was 130/80
mm Hg, and his respiration rate was 18
breaths/min. He appeared uncomfortable,
with rebound tenderness in the RLQ and
voluntary guarding; results of stool guai-
ac-based testing for occult blood were
negative.
Abdominal radiographs showed dilated
small bowel loops. Abdominal CT re-
vealed terminal ileum wall thickening con-
sistent with ileitis. The patient’s WBC
count was 9900 cells/mL (82% neutro-
phils), and his hemoglobin level was 14.9
g/dL. Results of chemistry testing were
normal, except for an albumin level of 3.3
g/dL and an alanine aminotransferase level
of 47 U/L. Ciprofloxacin and metroni-
dazole therapy was started, and the surgery
department was consulted. Their impres-
sion was that the patient had acute ter-
minal ileitis. He was admitted for intra-
venous hydration therapy and bowel rest
and continued to receive antibiotic treat-
ment and to undergo monitoring.
During the 24 h after admission, severe
abdominal pain persisted, which required
intravenous narcotics. His temperature in-
creased to 40.0C. Further questioning re-
vealed that, 1 week before the onset of
symptoms, he was bitten by a tick in a
rural park in upstate New York. He re-
moved and kept the “large” tick. He de-
nied having had any subsequent rash. An
eschar at the site of the tick bite was noted
